38O
4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one
Created: | 2014-07-09 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 50 |
Chiral Atom Count | 0 |
Bond Count | 54 |
Aromatic Bond Count | 16 |
Chemical Component Summary | |
---|---|
Name | 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one |
Synonyms | Dovitinib |
Systematic Name (OpenEye OEToolkits) | 4-azanyl-5-fluoranyl-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one |
Formula | C21 H21 F N6 O |
Molecular Weight | 392.429 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | Fc1cccc2c1C(N)=C(C(=O)N2)c4nc5cc(N3CCN(C)CC3)ccc5n4 |
SMILES | CACTVS | 3.385 | CN1CCN(CC1)c2ccc3[nH]c(nc3c2)C4=C(N)c5c(F)cccc5NC4=O |
SMILES | OpenEye OEToolkits | 1.9.2 | CN1CCN(CC1)c2ccc3c(c2)nc([nH]3)C4=C(c5c(cccc5F)NC4=O)N |
Canonical SMILES | CACTVS | 3.385 | CN1CCN(CC1)c2ccc3[nH]c(nc3c2)C4=C(N)c5c(F)cccc5NC4=O |
Canonical SMILES | OpenEye OEToolkits | 1.9.2 | CN1CCN(CC1)c2ccc3c(c2)nc([nH]3)C4=C(c5c(cccc5F)NC4=O)N |
InChI | InChI | 1.03 | InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29) |
InChIKey | InChI | 1.03 | PIQCTGMSNWUMAF-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB05928 |
---|---|
Name | Dovitinib |
Groups | investigational |
Description | Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib. |
Synonyms |
|
Indication | Investigated for use/treatment in multiple myeloma and solid tumors. |
Categories |
|
CAS number | 405169-16-6 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Nuclear receptor subfamily 1 group I member 2 | MEVRPKESWNHADFVHCEDTESVPGKPSVNADEEVGGPQICRVCGDKATG... | unknown | suppressor |
Cytochrome P450 1A1 | MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIG... | unknown | inducer |
Cytochrome P450 1A2 | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL... | unknown | inducer |
UDP-glucuronosyltransferase 1-3 | MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE... | unknown | inhibitor |
UDP-glucuronosyltransferase 2B7 | MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG... | unknown | inhibitor |
View More |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL522892 |
PubChem | 135398510 |
ChEMBL | CHEMBL522892 |
ChEBI | CHEBI:91395 |